Literature DB >> 7204716

Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients.

M H Bierman, C A Needham-Walker, M Hammeke, J D Egan.   

Abstract

Vancomycin therapy during 7 episodes of serious staphylococcal infections in chronic hemodialysis patients was monitored by a sensitive bioassay technique. One gm of vancomycin was given during dialysis at a mean dosage interval of 7 days for a mean duration of 48 days. Serum peak and trough vancomycin levels were monitored during therapy. Accumulation of vancomycin occurred in 1 patient on prolonged therapy; progressive rising through levels required a reduction in vancomycin dosage. Pre and post-dialysis vancomycin levels in one patient were unchanged. Vancomycin was effective in eradication of all staphylococcal infections and bacteremias. Three A-V shunt infections required surgical revision; 2 A-V fistula infections were salvaged with vancomycin therapy alone. We conclude that 1 gm vancomycin every 7 days is an effective regimen for serious staphylococcal infections in chronic hemodialysis patients. Monitoring of vancomycin levels insures maintenance of adequate levels and prevents toxic accumulation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7204716     DOI: 10.3109/08860228009065341

Source DB:  PubMed          Journal:  J Dial        ISSN: 0362-8558


  3 in total

1.  Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

Authors:  J Böhler; P Reetze-Bonorden; E Keller; A Kramer; P J Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 3.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.